Skip to main navigation Skip to search Skip to main content

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

  • ELOQUENT-1 investigators

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Fingerprint

Dive into the research topics of 'Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology